

cqdm **An innovative response to the pharmaceutical industry's challenges**



**Max Fehlmann,
President and CEO**

UQAM, September 29, 2009

Consortium québécois sur la découverte du médicament

cqdm

The immense pressure on the bio-pharma industry....

- **58.7** billion invested in R&D in 2007
- Poor innovative product pipelines
- Increasing regulatory hurdles
- Disillusion from expectations of rapid translation from "genes to drugs"

... requires to rethink its operational model and improve productivity

- A fostered co-creation of value between academic centers, biotech companies and the pharmaceutical industry
- The possibility to finance creative pre-competitive research with the potential to impact the whole life science sector
- A more flexible management of IP processes
- A better way to channel public funds on research agendas responding to Industry and Regulators needs

Consortium québécois sur la découverte du médicament

cqdm An innovative consortium in drug discovery

Our mission



- To identify, finance and support innovative research activities, primarily focusing on enabling technologies in drug discovery, fulfilling the innovation needs of the pharmaceutical industry
- To create a collaborative ground between the academic and private sectors based on trust, creativity and mutual benefit


Consortium québécois sur la découverte du médicament

cqdm Founding Partners



Consortium québécois sur la découverte du médicament





cqdm An annual forum to identify the needs of the industry


cqdm **MONTRÉAL invIVO**

Creative Partnerships in Biopharmaceutical Research


Montreal, June 8th, 2009

Consortium québécois sur la découverte du médicament

**Annual Forum 2009: Pfizer Canada, AstraZeneca Canada & Merck Frosst Canada
Bottlenecks in Biopharmaceutical Research**



Bernard Prigent
Pfizer Canada



Joe Vacca
Merck Frosst



Philippe
Walker
AstraZeneca
Canada



Consortium québécois sur la découverte du médicament

**Annual Forum 2009: the Round table *Creating Value through new opportunities
in Biopharmaceutical research***



Gilles Duruflé



JF Leprince



Patrice Roy



Yves Rosconi



Marc Leroux




Philip Barker



Consortium québécois sur la découverte du médicament

cqdm An innovative consortium



Benefits to Biotech companies and to academic institutions

- Additional source of funding
- Access to specialized and dedicated resources
- Closer links with industrial colleagues
- Increased international competitiveness

Consortium québécois sur la découverte du médicament